iqvia weight loss drug prescriptions q3 2024 semaglutide tirzepatide GLP-1 Antagonists Increase Plan Drug Spend Frequently Asked Questions (FAQs) on

Esta titulacin progresiva ayuda a minimizar los efectos secundarios gastrointestinales comunes durante las primeras semanas de tratamiento

Those taking the medication lost an average of 8.4 pounds over 29 weeks, compared to no weight loss for people taking a placebo

The overall GI side effect profile differs between the two medications

These results should be interpreted in light of study limitations, including the exclusion of patients who discontinued treatment early, non-randomized treatment allocation, unmeasured adherence to dietary and physical activity recommendations, and variability in dose escalation and intensity